These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 38936923)

  • 1. C-reactive Protein Is a Prognostic Factor for Survival in Metastatic Upper Tract Urothelial Carcinoma Patients Receiving Pembrolizumab.
    Nagasaka H; Yamamoto S; Suzuki A; Usui K; Terao H; Nakaigawa N; Kishida T
    In Vivo; 2024; 38(4):1823-1828. PubMed ID: 38936923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Antacids on the Survival of Patients With Metastatic Urothelial Carcinoma Treated With Pembrolizumab.
    Sekito T; Bekku K; Katayama S; Watanabe T; Tsuboi I; Yoshinaga K; Maruyama Y; Yamanoi T; Kawada T; Tominaga Y; Sadahira T; Iwata T; Nishimura S; Kusumi N; Edamura K; Kobayashi T; Kurose K; Ichikawa T; Miyaji Y; Wada K; Kobayashi Y; Araki M
    Clin Genitourin Cancer; 2024 Aug; 22(4):102097. PubMed ID: 38763123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic outcomes and safety in patients treated with pembrolizumab for advanced urothelial carcinoma: experience in real-world clinical practice.
    Tamura D; Jinnouchi N; Abe M; Ikarashi D; Matsuura T; Kato R; Maekawa S; Kato Y; Kanehira M; Takata R; Obara W
    Int J Clin Oncol; 2020 May; 25(5):899-905. PubMed ID: 31907720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enfortumab vedotin prolongs overall survival in metastatic urothelial carcinoma following pembrolizumab therapy in real-world data.
    Uemura K; Ito H; Jikuya R; Kondo T; Tatenuma T; Kawahara T; Ito Y; Komeya M; Muraoka K; Hasumi H; Uemura H; Makiyama K
    Int J Urol; 2024 Jun; 31(6):678-684. PubMed ID: 38402449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic role of circulating cytokines and inflammation indexes for avelumab maintenance in metastatic urothelial carcinoma.
    Maiorano BA; Schinzari G; Carbone C; Piro G; Rossi E; Di Maio M; Di Giacomo A; Maiello E
    Front Immunol; 2024; 15():1401214. PubMed ID: 38799450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The poor antitumor effect of pembrolizumab in advanced upper urothelial carcinoma with renal parenchymal invasion.
    Hara T; Furukawa J; Okamura Y; Bando Y; Terakawa T; Harada K; Takahashi S; Nakano Y; Fujisawa M
    Int J Urol; 2023 Sep; 30(9):779-786. PubMed ID: 37317886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract.
    Sternberg CN; Loriot Y; James N; Choy E; Castellano D; Lopez-Rios F; Banna GL; De Giorgi U; Masini C; Bamias A; Garcia Del Muro X; Duran I; Powles T; Gamulin M; Zengerling F; Geczi L; Gedye C; de Ducla S; Fear S; Merseburger AS
    Eur Urol; 2019 Jul; 76(1):73-81. PubMed ID: 30910346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes.
    Esagian SM; Khaki AR; Diamantopoulos LN; Carril-Ajuria L; Castellano D; De Kouchkovsky I; Park JJ; Alva A; Bilen MA; Stewart TF; McKay RR; Santos VS; Agarwal N; Jain J; Zakharia Y; Morales-Barrera R; Devitt ME; Nelson A; Hoimes CJ; Shreck E; Gartrell BA; Sankin A; Tripathi A; Zakopoulou R; Bamias A; Rodriguez-Vida A; Drakaki A; Liu S; Kumar V; Lythgoe MP; Pinato DJ; Murgic J; Fröbe A; Joshi M; Isaacsson Velho P; Hahn N; Alonso Buznego L; Duran I; Moses M; Barata P; Galsky MD; Sonpavde G; Yu EY; Msaouel P; Koshkin VS; Grivas P
    BJU Int; 2021 Aug; 128(2):196-205. PubMed ID: 33556233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association Between Serum Magnesium Levels and Outcomes of Atezolizumab in Patients With Metastatic Urothelial Carcinoma.
    Fukuokaya W; Akazawa K; Kimura T
    Anticancer Res; 2024 May; 44(5):2117-2123. PubMed ID: 38677745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive Impact of Prognostic Nutritional Index on Pembrolizumab for Metastatic Urothelial Carcinoma Resistant to Platinum-based Chemotherapy.
    Ishiyama Y; Kondo T; Nemoto Y; Kobari Y; Ishihara H; Tachibana H; Yoshida K; Hashimoto Y; Takagi T; Iizuka J; Tanabe K
    Anticancer Res; 2021 Mar; 41(3):1607-1614. PubMed ID: 33788756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between comorbidities and survival in patients with metastatic urothelial carcinoma treated with pembrolizumab.
    Hashimoto M; Fukuokaya W; Yanagisawa T; Yamamoto S; Koike Y; Imai Y; Iwatani K; Onuma H; Ito K; Urabe F; Tsuzuki S; Kimura S; Oyama Y; Abe H; Miki J; Kimura T
    Int J Clin Oncol; 2024 May; 29(5):612-619. PubMed ID: 38430304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The comparison of oncologic outcomes between metastatic upper tract urothelial carcinoma and urothelial carcinoma of the bladder after cisplatin-based chemotherapy.
    Hsieh MC; Chiang PH; Rau KM; Chen YY; Su YL; Huang CH
    Urol Oncol; 2015 Nov; 33(11):495.e9-495.e14. PubMed ID: 26254698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: a subgroup analysis of the phase 3 KEYNOTE-045 trial.
    Nishiyama H; Yamamoto Y; Sassa N; Nishimura K; Fujimoto K; Fukasawa S; Yokoyama M; Enokida H; Takahashi K; Tanaka Y; Imai K; Shimamoto T; Perini R; Frenkl T; Bajorin D; Bellmunt J
    Int J Clin Oncol; 2020 Jan; 25(1):165-174. PubMed ID: 31729625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early C-reactive protein kinetics predict survival of patients with advanced urothelial cancer treated with pembrolizumab.
    Kijima T; Yamamoto H; Saito K; Kusuhara S; Yoshida S; Yokoyama M; Matsuoka Y; Numao N; Sakai Y; Matsubara N; Yuasa T; Masuda H; Yonese J; Kageyama Y; Fujii Y
    Cancer Immunol Immunother; 2021 Mar; 70(3):657-665. PubMed ID: 32876736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expressions of PD-L1 and Nectin-4 in urothelial cancer patients treated with pembrolizumab.
    Ueki H; Hinata N; Kitagawa K; Hara T; Terakawa T; Furukawa J; Harada K; Nakano Y; Komatsu M; Fujisawa M; Shirakawa T
    Clin Transl Oncol; 2022 Mar; 24(3):568-577. PubMed ID: 34687441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study.
    Balar AV; Castellano D; O'Donnell PH; Grivas P; Vuky J; Powles T; Plimack ER; Hahn NM; de Wit R; Pang L; Savage MJ; Perini RF; Keefe SM; Bajorin D; Bellmunt J
    Lancet Oncol; 2017 Nov; 18(11):1483-1492. PubMed ID: 28967485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Onychomadesis following pembrolizumab treatment for metastatic urothelial carcinoma: A report of two cases.
    Sugihara Y; Kawai T; Yamada D; Furuyama C; Sato Y; Kume H
    Eur J Cancer; 2020 Feb; 126():91-92. PubMed ID: 31923731
    [No Abstract]   [Full Text] [Related]  

  • 18. Cost-effectiveness of Pembrolizumab for Patients with Advanced, Unresectable, or Metastatic Urothelial Cancer Ineligible for Cisplatin-based Therapy.
    Patterson K; Prabhu V; Xu R; Li H; Meng Y; Zarabi N; Zhong Y; Batteson R; Pellissier J; Keefe S; Grivas P; de Wit R
    Eur Urol Oncol; 2019 Sep; 2(5):565-571. PubMed ID: 31412011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blood Cell Count Biomarkers Predicting Efficacy of Pembrolizumab as Second-line Therapy for Advanced Urothelial Carcinoma.
    Kadono Y; Kawaguchi S; Nohara T; Shigehara K; Izumi K; Kamijima T; Seto C; Takano A; Yotsuyanagi S; Nakagawa R; Miyagi T; Aoyama S; Asahi H; Fukuda R; Mizokami A
    Anticancer Res; 2021 Mar; 41(3):1599-1606. PubMed ID: 33788755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk stratification for the prognosis of patients with chemoresistant urothelial cancer treated with pembrolizumab.
    Kobayashi T; Ito K; Kojima T; Kato M; Kanda S; Hatakeyama S; Matsui Y; Matsushita Y; Naito S; Shiga M; Miyake M; Muro Y; Nakanishi S; Kato Y; Shibuya T; Hayashi T; Yasumoto H; Yoshida T; Uemura M; Taoka R; Kamiyama M; Ogawa O; Kitamura H; Nishiyama H;
    Cancer Sci; 2021 Feb; 112(2):760-773. PubMed ID: 33283385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.